Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 <scp>UNIFI</scp> Study of Ustekinumab in Ulcerative Colitis

Authors

Bruce E. Sands (ORCID: https://orcid.org/0000-0001-5762-5042)
Rupert W. Leong (ORCID: https://orcid.org/0000-0001-5944-3488)
Laurent Peyrin‐Biroulet (ORCID: https://orcid.org/0000-0003-2536-6618)
Silvio Danese (ORCID: https://orcid.org/0000-0001-7341-1351)
Colleen W Marano (ORCID: https://orcid.org/0000-0002-4965-5142)
Tony Ma (ORCID: https://orcid.org/0000-0003-3629-8278)

Institutions

Johnson & Johnson (United States) (US)
Inserm (FR)
Concord Repatriation General Hospital (AU)
McGill University Health Centre (CA)
IRCCS Ospedale San Raffaele (IT)
Nutrition-Génétique et Exposition aux Risques Environnementaux (FR)
Université de Lorraine (FR)
Icahn School of Medicine at Mount Sinai (US)
Macquarie University (AU)

Publication Details

Journal: Alimentary Pharmacology & Therapeutics
Published: 2025-07-16
DOI: https://doi.org/10.1111/apt.70264
Citations: 2
Primary Topic: Inflammatory Bowel Disease
Type: article
Field-Weighted Citation Impact: 3.63

Funders

Johnson and Johnson

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis

Bruce E. Sands, Rupert W. Leong, Laurent Peyrin‐Biroulet, Silvio Danese et al.

Jul 16, 2025

2 citations

Alimentary Pharmacology & Therapeutics

Inflammatory Bowel Disease

3.63

article

Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis

Bruce E. Sands, Rupert W. Leong, Laurent Peyrin‐Biroulet, Silvio Danese, Colleen W Marano, Tony Ma

July 16, 2025article en

2 citations

Abstract

No abstract available for this paper.

Alimentary Pharmacology & TherapeuticsVol. 62(5)

Johnson & Johnson (United States) (US), Inserm (FR), Concord Repatriation General Hospital (AU), McGill University Health Centre (CA), IRCCS Ospedale San Raffaele (IT), Nutrition-Génétique et Exposition aux Risques Environnementaux (FR), Université de Lorraine (FR), Icahn School of Medicine at Mount Sinai (US), Macquarie University (AU)

Johnson and Johnson

Good health and well-being

Openalex Percentile: Top 7%

Inflammatory Bowel Disease

3.63

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 <scp>UNIFI</scp> Study of Ustekinumab in Ulcerative Colitis — Bruce E. Sands, Rupert W. Leong, et al. · Alimentary Pharmacology & Therapeutics (2025) | TGRS Research Map | TGRS